Enzyme-responsive Nanoparticles for Drug Release and Diagnostics
Overview
Affiliations
Enzymes are key components of the bionanotechnology toolbox that possess exceptional biorecognition capabilities and outstanding catalytic properties. When combined with the unique physical properties of nanomaterials, the resulting enzyme-responsive nanoparticles can be designed to perform functions efficiently and with high specificity for the triggering stimulus. This powerful concept has been successfully applied to the fabrication of drug delivery schemes where the tissue of interest is targeted via release of cargo triggered by the biocatalytic action of an enzyme. Moreover, the chemical transformation of the carrier by the enzyme can also generate therapeutic molecules, therefore paving the way to design multimodal nanomedicines with synergistic effects. Dysregulation of enzymatic activity has been observed in a number of severe pathological conditions, and this observation is useful not only to program drug delivery in vivo but also to fabricate ultrasensitive sensors for diagnosing these diseases. In this review, several enzyme-responsive nanomaterials such as polymer-based nanoparticles, liposomes, gold nanoparticles and quantum dots are introduced, and the modulation of their physicochemical properties by enzymatic activity emphasized. When known, toxicological issues related to the utilization nanomaterials are highlighted. Key examples of enzyme-responsive nanomaterials for drug delivery and diagnostics are presented, classified by the type of effector biomolecule, including hydrolases such as proteases, lipases and glycosidases, and oxidoreductases.
Nanomaterials for targeted therapy of kidney diseases: Strategies and advances.
Wang Z, Zhang C Mater Today Bio. 2025; 31:101534.
PMID: 39990736 PMC: 11846943. DOI: 10.1016/j.mtbio.2025.101534.
Responsive nanomaterials in biomedicine, patent path and prospect analysis.
Liu X, Yuan H Front Bioeng Biotechnol. 2025; 13:1539991.
PMID: 39968009 PMC: 11832473. DOI: 10.3389/fbioe.2025.1539991.
CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.
Lee H, Rho W, Kim Y, Chang H, Jun B Molecules. 2025; 30(3).
PMID: 39942646 PMC: 11820414. DOI: 10.3390/molecules30030542.
Zhang Q, Wang Z, Shen S, Wang J, Cao J, Deng Y Front Cell Infect Microbiol. 2024; 14:1494651.
PMID: 39554809 PMC: 11564189. DOI: 10.3389/fcimb.2024.1494651.
Mishra A, Kumar R, Harilal S, Nigam M, Datta D, Singh S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):497-532.
PMID: 39480523 DOI: 10.1007/s00210-024-03469-x.